Physician profile
Frank Sharp
NPI 1861465338
$6,308.51
in general payments reported to CMS, 2019-2025
31 companies · $1,231 in 2025
The $1,231 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $321 · 2021: $516 · 2022: $475 · 2023: $863 · 2024: $2,680 · 2025: $1,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,774.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,573.92 | 2021-2025 | Abre, Endurant Iis, Micra |
| Endologix LLC | $1,133.99 | 2020-2024 | Alto Abdominal Stent Graft System, Torus Stent Graft System, Endocross Device |
| Janssen Pharmaceuticals, INC | $487.56 | 2019-2024 | Xarelto |
| Bard Peripheral Vascular, INC. | $289.19 | 2019-2025 | Rotarexs 6 F X 135 Cm, Venovo |
| W. L. Gore & Associates, INC. | $282.14 | 2024-2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis, Gore Excluder Aaa Endoprosthesis, Gore Viabahn Vbx Balloon Expandable Endo |
| Stryker Corporation | $170.86 | 2025 | Clottriever Bold Catheter |
| Boston Scientific Corporation | $156.97 | 2021-2025 | Eluvia, Enroute Transcarotid Neuroprotection System |
| Artivion, INC. | $130.45 | 2020-2022 | |
| Smith+Nephew, INC. | $127.53 | 2019-2025 | Pico 7, Renasys Touch |
| Inari Medical, INC. | $125.76 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Angiodynamics, INC. | $107.97 | 2019-2025 | Auryon Laser System 100-120 Vac |
| Globus Medical, INC. | $81.74 | 2024 | Alif |
| Silk Road Medical, INC. | $72.89 | 2021-2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Biotronik INC. | $61.88 | 2022-2023 | Pulsar-18 T3 |
| Medtronic Vascular, INC. | $56.92 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $55.37 | 2025 | Restrata Wound Matrix |
| Abbott Laboratories | $44.53 | 2019-2025 | Esprit |
| Shockwave Medical, INC | $43.40 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $42.72 | 2021-2024 | Eliquis |
| Ethicon US, LLC | $42.65 | 2024-2025 | Vistaseal, Ethicon |
| Integra Lifesciences Corporation | $34.52 | 2022 | |
| Pfizer INC. | $34.44 | 2023-2024 | |
| Cardiva Medical, INC. | $26.80 | 2025 | Cardiva Vascade 6/7f Vcs |
| Cvrx, INC. | $19.51 | 2024 | Barostim Neo System |
| Becton, Dickinson and Company | $18.92 | 2019 | |
| Novo Nordisk INC | $16.50 | 2023 | Rybelsus, Ozempic |
| Cordis US Corp. | $14.93 | 2025 | Mynx Control |
| Misonix INC | $14.73 | 2020 | |
| Cardinal Health 200 LLC | $14.40 | 2020 | |
| Kci USA, INC. | $14.16 | 2023 | V.A.C.Ulta, V.A.C. Veraflo, Prevena |
| Terumo Medical Corporation | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.